RecruitingPhase 1

A Study of CDX-622 in Participants With Mild to Moderate Asthma

United States12 participantsStarted 2026-02

Plain-language summary

This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Males and females, ≥ 18 years of age
✓. Diagnosis of mild to moderate asthma for at least 12 months
✓. Pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 70% of predicted normal
✓. Airway reversibility ≥ 12% and 200 mL improvement in FEV1
✓. Both males and females of child-bearing potential must agree to use contraception during the study and for 150 days after treatment
✓. Willing and able to comply with all study requirements and procedures

✕. Females who are pregnant or nursing
✕. Pulmonary disease other than asthma
✕. Systemic diseases with elevated eosinophils other than asthma
✕. Hospitalization or oral corticosteroids due to asthma within the past 6 months
✕. History of needing ventilator support due to asthma
✕. Current nasal polyps
✕. Severe or uncontrolled asthma
✕. History of smoking or vaping within the past 12 months

To evaluate the safety and tolerability profile of CDX-622 in adults with mild to moderate asthma.

Timeframe: Day 1 up to Day 85 (12 weeks)

NCT IDNCT07330778

SponsorCelldex Therapeutics

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-03

Celldex Therapeutics